LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Position Decreased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 25.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 35,267 shares of the medical instruments supplier's stock after selling 11,916 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.16% of LeMaitre Vascular worth $3,276,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Driehaus Capital Management LLC raised its position in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock valued at $21,740,000 after acquiring an additional 90,573 shares in the last quarter. F M Investments LLC bought a new stake in LeMaitre Vascular during the second quarter valued at $7,443,000. Nicholas Investment Partners LP acquired a new stake in shares of LeMaitre Vascular during the second quarter worth $3,900,000. Conestoga Capital Advisors LLC lifted its position in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier's stock worth $183,769,000 after buying an additional 36,850 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its holdings in shares of LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier's stock valued at $24,273,000 after buying an additional 35,383 shares during the period. Institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Up 0.4 %

LMAT stock traded up $0.41 during trading on Friday, reaching $100.69. 183,716 shares of the company's stock were exchanged, compared to its average volume of 124,557. LeMaitre Vascular, Inc. has a 1-year low of $52.88 and a 1-year high of $109.58. The firm has a market cap of $2.26 billion, a PE ratio of 55.02, a P/E/G ratio of 2.47 and a beta of 0.93. The company's fifty day moving average price is $97.65 and its 200-day moving average price is $89.54.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the prior year, the company posted $0.33 earnings per share. The company's quarterly revenue was up 15.6% compared to the same quarter last year. As a group, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 5th. Investors of record on Thursday, November 21st were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.64%. LeMaitre Vascular's payout ratio is 34.97%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.79% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Barrington Research increased their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target on the stock. JMP Securities boosted their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 20th. StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday. Finally, Oppenheimer reissued an "outperform" rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.